CURRENT ISSUE
June, 2021

No. 106 (6)

2019 Impact Factor: 7.116
ARTICLES IN THREE SENTENCES
Article

Oncorequisite role of an aldehyde dehydrogenase in the pathogenesis of T-cell acute lymphoblastic leukemia

One of the ALDH family genes, ALDH1A2, is aberrantly expressed in more than 50% of cases of T-cell acute lymphoblastic leukemia. This study revealed that ALDH1A2 protects against intracellular stress and promotes T-ALL cell metabolism and survival. ALDH1A2 overexpression enables leukemic clones to sustain a hyper-proliferative state driven by oncogenes.

Chujing Zhang et al.

Article

Natural estrogens enhance the engraftment of human hematopoietic stem and progenitor cells in immunodeficient mice

This study found that hematopoietic stem and progenitor cells subsets express estrogen receptors, and that signaling is activated by estradiol and estetrol. Estetrol enhanced human reconstitution in immunodeficient mice directly, by modulating human hematopoietic progenitor properties, and indirectly, by interacting with the bone marrow niche. This might have particular relevance for improving hematopoietic recovery after myeloablative conditioning, especially when limited numbers of HSPC are available.

Sara Fañanas-Baquero et al.

Article

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas

A phase I/II multi-center trial used six cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for treatment of CD30-positive B-cell lymphomas. The overall response rate was 100% with 86% of patients achieving complete response. The 2-year progression-free survival and overall survival rates were 85% and 100%.

Jakub Svoboda et al.

Letter

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database

This is a retrospective, observational study in the realworld of 1,256 patients with myeloma treated with bortezomib-based induction chemotherapy followed by autologous stem cell transplant; 57.6% of patients received lenalidomide maintenance and 42.4% did not. Maintenance had positive impact on response, progression free survival and overall survival. This supports maintenance with lenalidomide as a standard of care.

Hannah M. Cherniawsky et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA